Affordable Access

IGF-I and diabetes in adolescence.

Authors
Type
Published Article
Journal
Diabetes & Metabolism
1262-3636
Publisher
Elsevier
Publication Date
Volume
24
Issue
2
Pages
101–107
Identifiers
PMID: 9592633
Source
Medline

Abstract

Adolescents with insulin-dependent diabetes mellitus (IDDM) often experience difficulties achieving good glycaemic control, and attempts at intensifying insulin therapy may increase the risk of hypoglycaemia and weight gain. Abnormalities of the GH/IGF-I axis may contribute to these problems. Insulin-like growth factor-I (IGF-I) levels and IGF bioactivity are invariably reduced despite growth hormone (GH) hypersecretion, and these abnormalities are only partially corrected by intensified insulin therapy. The administration of recombinant human IGF-I (rhIGF-I) as an adjunct to insulin therapy can restore circulating IGF-I levels and thus suppress GH levels and improve insulin sensitivity. Randomised placebo-controlled clinical trials of daily subcutaneous rhIGF-I therapy (40-80 micrograms/kg/day) have demonstrated that significant reductions in HbA1c can be achieved without evidence of toxicity or exacerbation of diabetic complications. RhIGF-I used in conjunction with insulin may therefore provide an additional approach to the management of IDDM during adolescence, although further studies are required to determine the ideal dose regimen and confirm beneficial effects without adverse effects on microvascular complications in these subjects.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments